Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on November 9, 2026 reporting Item EX-99.3 (Exhibit EX-99.3). Pro forma combined revenue $321.2M and net income $11.8M for nine months ended September 30, 2026.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.3 · Exhibit EX-99.3
- Pro forma combined revenue $321.2M and net income $11.8M for nine months ended September 30, 2026
- Full-year 2025 pro forma revenue $213.4M, but net loss $43.7M after merger and financing adjustments
- Theravance acquisition required $560.4M net consideration after $355.2M cash acquired, creating $104.4M preliminary goodwill
- YUPELRI profit-sharing rights valued at $415.4M, the primary acquired asset and earnings driver
- $350M notes at 8.25% mature December 31, 2036, with 75% of U.S. YUPELRI profit-share cash flows assigned to debt service
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.